Preferential allotment funded by the company itself was treated as a false capital infusion and fraudulent market conduct.

A listed company's preferential allotment funded by its own money was treated as a false appearance of genuine capital infusion and, therefore, a fraudulent and unfair trade practice under Section 12A of the SEBI Act and Regulations 3 and 4 of the PFUTP Regulations. The tribunal accepted that investor understanding of preferential allotment is fresh capital into the company; when the company itself finances the subscription, the transaction misleads the market. Explanations that the funds were an advance, loan, or adjustment against future fees were rejected, especially because the appellants took shifting stands. The penalty was upheld.

---

---

Issues: Whether preferential allotment of shares was funded by the company itself so as to create a false impression of genuine capital infusion and thereby constitute a fraudulent and unfair trade practice in violation of Section 12A of the SEBI Act and Regulations 3 and 4 of the PFUTP Regulations.

Analysis: The admitted position was that the company transferred its own funds to the preferential allottees to enable them to subscribe to its shares. Such an arrangement does not amount to genuine infusion of capital because a listed company's preferential allotment is ordinarily understood by investors as fresh capital being brought into the company. When the company itself finances the allotment, it misleads the market by projecting an apparent capital infusion that is not real. The appellants' explanation that the funds were an advance, loan, or adjustment against future professional fees was not accepted, especially in view of the shifting stand taken at different stages.

Conclusion: The financing of the preferential allotment by the company itself amounted to a fraudulent act and an unfair device prohibited by Section 12A of the SEBI Act read with Regulations 3 and 4 of the PFUTP Regulations. The penalty was upheld and the appeal failed.

Ratio Decidendi: Where a listed company funds preferential allottees with its own money to subscribe to its shares, the transaction creates a false appearance of capital infusion and constitutes fraud and an unfair trade practice under the SEBI anti-fraud framework.

---